The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer

Molecular profiling has revolutionized the diagnosis and management of patients with non‐small cell lung cancer (NSCLC), enabling personalized treatment approaches that have significantly improved patient outcomes. Identifying specific gene mutations and protein expression profiles guides therapeutic decisions and has become standard in the management of patients with NSCLC. Multiple organizations have published guidelines for biomarker testing. However, differences in the timing, methodology, and scope of recommended targets create potential for inconsistencies in clinical practice. This article reviews the clinical importance of biomarker testing in NSCLC, compares major guidelines, and highlights the challenges and implications of guideline variability in formulating recommendations on biomarker testing for patients with NSCLC.